Abstract
Background: To determine the demographic details and management choices of anti-epileptic drugs (AEDs) for the newly diagnosed epilepsy patients in India.Methods: This was a retrospective, observational study conducted among newly diagnosed epilepsy patients in India between Apr 2021 and Mar 2022. The demographic parameters, treatment given, adherence to treatment, and clinician’s global assessment for effectiveness and safety of management options were evaluated.Results: Out of 20,343 patients, majority of the patients were aged between 31-50 years (54.5%), and 62.7% of them were males. Majority of the patients were diagnosed with focal epilepsy (72.2%). Migraine was the most common (28.3%) neuropsychiatric comorbidity among these patients followed by anxiety (19.7%), stroke (18.5%) and depression (11.2%); other commonly reported comorbidities were hypertension (38.27%), gastrointestinal disorders (25.39%), and diabetes (22.06%). Levetiracetam (49.6%) was the most commonly prescribed AED, followed by valproate (29.1%), oxcarbazepine (15.5%), clobazam (13.3%) and lacosamide (8%). With the prescribed AEDs, majority (91%) of the patients had decrease in seizure frequency, most (99.2%) patients had ‘good to excellent’ adherence to the therapy, and clinicians rated the efficacy and safety of prescribed drugs as ‘good to excellent’ in most (99.9%) patients.Conclusions: Epilepsy was common in patients aged 30-50 years with male preponderance. Focal epilepsy was more prevalent. Overall levetiracetam was the most prescribed AED. Levetiracetam and valproate were the most prescribed AEDs among focal and generalized epilepsy respectively. AEDs were well tolerated by most of the patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal Of Community Medicine And Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.